戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Budd et al. challenge the identity of neural traces repo
2                                              Budd-Chiari syndrome (BCS) and portal vein thrombosis ha
3                                              Budd-Chiari syndrome (BCS) is a rare condition associate
4                                              Budd-Chiari syndrome (BCS) is a rare, life-threatening d
5                                              Budd-Chiari syndrome (BCS) is uncommon in the children.
6                                              Budd-Chiari Syndrome (BCS) results from obstruction to h
7                                              Budd-Chiari syndrome, occlusion or obstruction of hepati
8                                              Budd-Chiari-like syndrome in dolphins is hypothesized ba
9 flow obstruction, which presents as an acute Budd-Chiari syndrome.
10                    Either acute or sub-acute Budd-Chiari syndrome (BCS) with diffuse occlusion of hep
11 an lead to hepatic congestion, cirrhosis and Budd-Chiari syndrome (BCS) and can predispose to develop
12 arcoidosis, congenital hepatic fibrosis, and Budd-Chiari syndrome.
13 atichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.
14 e frequently the venous system, typically as Budd-Chiari syndrome.
15 e described in the context of heart disease, Budd-Chiari syndrome, and the sinusoidal obstruction syn
16 d with autoimmune hepatitis, Wilson disease, Budd-Chiari syndrome, hepatitis B virus reactivation, in
17 ngs included hepatofugal portal venous flow, Budd-Chiari syndrome, cavernous transformation of the po
18 o orthotopic liver transplantation (OLT) for Budd-Chiari syndrome (BCS) traditionally have been antic
19       TIPS has also been used as therapy for Budd-Chiari syndrome and veno-occlusive disease.
20 ic and portal veins, resulting in functional Budd-Chiari syndrome and portal hypertension.
21 the outcome of liver transplantation (LT) in Budd-Chiari Syndrome (BCS) patients who are listed as st
22 s in patients with hepatic vein obstruction (Budd-Chiari Syndrome) and in those with portal vein thro
23 eoplasms (MPNs) are the most common cause of Budd-Chiari syndrome (BCS) and nonmalignant, noncirrhoti
24 ive disorders (MPDs) are a frequent cause of Budd-Chiari syndrome (BCS), treatment directed toward al
25                                Management of Budd-Chiari syndrome (BCS) has improved over the last de
26 e patient died at 1 month from tumor-related Budd-Chiari syndrome.
27      Giant invalidating tumor (5 HAS, 1 with Budd-Chiari syndrome [BCS], and 10 supposed epithelioid
28 dical records of all patients diagnosed with Budd-Chiari syndrome at the Johns Hopkins Hospital durin
29 ic shunt (TIPS) in a series of patients with Budd-Chiari syndrome (BCS), and to determine the predict
30                             In patients with Budd-Chiari syndrome and with portal vein thrombosis, Ki